Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutics to improve the lives of patients with serious diseases. The Company currently has three product candidates in clinical development covering multiple potential indications. Cabiralizumab (FPA008) is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis and in multiple cancers in combination with Bristol-Myers Squibb Company’s PD-1 immune checkpoint inhibitor, Opdivo (nivolumab). FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that we are initially developing to treat patients with gastric (stomach) cancer and is in a Phase 1 clinical trial. FP-1039 is a fusion protein that “traps” and neutralizes cancer-promoting fibroblast growth factors, or FGFs, involved in cancer cell proliferation and new blood vessel formation that is in Phase 1b clinical development to treat patients with malignant pleural mesothelioma.

Show more
Type
Public
HQ
South San Francisco, US
Founded
2001
Size (employees)
195 (est)
Five Prime Therapeutics was founded in 2001 and is headquartered in South San Francisco, US
Report incorrect company information

Key People/Management at Five Prime Therapeutics

Aron Knickerbocker

Aron Knickerbocker

Chief Operating Officer
Marc Belsky

Marc Belsky

Senior Vice President and Chief Financial Officer

Five Prime Therapeutics Office Locations

Five Prime Therapeutics has an office in South San Francisco
South San Francisco, US (HQ)
2 Corporate Dr
Show all (1)
Report incorrect company information

Five Prime Therapeutics Financials and Metrics

Five Prime Therapeutics Financials

USD

Net income (FY, 2017)

(150.2 m)

EBIT (FY, 2017)

(151.4 m)

Market capitalization (23-Apr-2018)

459.7 m

Cash (31-Dec-2017)

59.8 m
Five Prime Therapeutics's current market capitalization is $459.7 m.
Annual
USDFY, 2013FY, 2016FY, 2017

General and administrative expense

35.8 b40 m

R&D expense

94.1 b150.9 m

Operating expense total

129.9 b190.9 m

EBIT

(29.4 m)(99.2 b)(151.4 m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

General and administrative expense

4.6 m5.2 m8.6 b8.1 b9.1 b10.5 b9.4 m

R&D expense

13.3 m24.7 m18.3 b22.2 b23.9 b33.8 b41.7 m

Operating expense total

17.9 m29.9 m26.9 b30.3 b33 b44.2 b51.1 m52.4 b

EBIT

(11.6 m)(24.1 m)(20.4 b)(21.1 b)(26.4 b)(34.1 b)(43.3 m)(44.1 b)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

8.2 m15.3 m150 m7.7 m59.8 m

Accounts Receivable

Inventories

Current Assets

77.7 m151.3 m528.3 m440.1 m311.2 m
Quarterly
USDQ3, 2017

Accounts Payable

2.9 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(28.9 m)(37.4 m)249.6 m(65.7 m)(150.2 m)

Depreciation and Amortization

1.7 m1.6 m1.7 m1.7 m2.5 m

Inventories

Accounts Payable

(209 k)701 k798 k(1.6 m)1.9 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(11.5 m)(24 m)(13 b)(13.1 b)(19.4 b)(33.4 b)(43.3 b)

Accounts Payable

3.8 m347 k767 k672 k904 k1.4 m1.6 m1 m654 k528 k807 k1.3 m2.9 m
USDY, 2017

Financial Leverage

1.3 x
Show all financial metrics
Report incorrect company information